Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.

Fernando K, Fernando N, Welhenge C, Liyanage S, Dayanath BKTP, De Silva S, Mettananda C

Open source

DOI
10.1186/s13063-025-08943-2
Published
2025 Sep 1
Container
Trials
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s13063-025-08943-2,
  title = {Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.},
  author = {Fernando K and Fernando N and Welhenge C and Liyanage S and Dayanath BKTP and De Silva S and Mettananda C},
  year = {2025},
  journal = {Trials},
  doi = {10.1186/s13063-025-08943-2},
  url = {https://doi.org/10.1186/s13063-025-08943-2}
}

RIS

TY  - JOUR
TI  - Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.
AU  - Fernando K
AU  - Fernando N
AU  - Welhenge C
AU  - Liyanage S
AU  - Dayanath BKTP
AU  - De Silva S
AU  - Mettananda C
PY  - 2025
JO  - Trials
DO  - 10.1186/s13063-025-08943-2
UR  - https://doi.org/10.1186/s13063-025-08943-2
ER  - 

APA

K, F., N, F., C, W., S, L., BKTP, D., S, D. S., & C, M. (2025). Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.. Trials. https://doi.org/10.1186/s13063-025-08943-2

Source records